Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode

被引:55
作者
Kranz, Michael [1 ]
Wall, Michael [1 ]
Evans, Brian [1 ]
Miah, Afjal [1 ]
Ballantine, Stuart [1 ]
Delves, Chris [1 ]
Dombroski, Brian [1 ]
Gross, Jeffrey [1 ]
Schneck, Jessica [1 ]
Villa, James P. [1 ]
Neu, Margarete [1 ]
Somers, Don O. [1 ]
机构
[1] GlaxoSmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England
关键词
Lead optimisation; Ligand docking; Induced fit; SAR; PHOSPHODIESTERASE; 4D; RAT-BRAIN; MECHANISM; PROTEIN; SULFUR;
D O I
10.1016/j.bmc.2009.03.061
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A PDE4B over 4D-selective inhibitor programme was initiated to capitalise on the recently discovered predominance of the PDE4B subtype in inflammatory cell regulation. The SAR of a tetrahydrobenzothiophene (THBT) series did not agree with either of two proposed docking modes in the 4B binding site. A subsequent X-ray co- crystal structure determination revealed that the THBT ligand displaces the Gln-443 residue, invariably ligand-anchoring in previous PDE4 co-crystal structures, and even shifts helix-15 by 1-2 angstrom. For the first time, several residues of the C-terminus previously proposed to be involved in subtype selectivity are resolved and three of them extend into the ligand binding site potentially allowing for selective drug design. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5336 / 5341
页数:6
相关论文
共 21 条
[1]   Hydrogen-bond acceptor and donor properties of divalent sulfur (Y-S-Z and R-S-H) [J].
Allen, FH ;
Bird, CM ;
Rowland, RS ;
Raithby, PR .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 1997, 53 :696-701
[2]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[3]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[4]   Structural basis for the activity of drugs that inhibit phosphodiesterases [J].
Card, GL ;
England, BP ;
Suzuki, Y ;
Fong, D ;
Powell, B ;
Lee, B ;
Luu, C ;
Tabrizizad, M ;
Gillette, S ;
Ibrahim, PN ;
Artis, DR ;
Bollag, G ;
Milburn, MV ;
Kim, SH ;
Schlessinger, J ;
Zhang, KYJ .
STRUCTURE, 2004, 12 (12) :2233-2247
[5]   PROPERTIES OF CYCLIC 3',K'-NUCLEOTIDE PHOSPHODIESTERASE FROM RAT BRAIN [J].
CHEUNG, WY .
BIOCHEMISTRY, 1967, 6 (04) :1079-&
[6]  
Dastidar SG, 2007, CURR OPIN INVEST DR, V8, P364
[7]   REACTION OF THIACYCLOPENTAN-3-ONE WITH CYANOACETIC ESTER AND SULFUR [J].
GEWALD, K ;
SCHAEL, J .
JOURNAL FUR PRAKTISCHE CHEMIE, 1973, 315 (01) :39-43
[8]  
Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/bj20021698
[9]   Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages [J].
Jin, SLC ;
Lan, L ;
Zoudilova, M ;
Conti, M .
JOURNAL OF IMMUNOLOGY, 2005, 175 (03) :1523-1531
[10]   Crystal structure of phosphodiesterase 4D and inhibitor complex [J].
Lee, ME ;
Markowitz, J ;
Lee, JO ;
Lee, H .
FEBS LETTERS, 2002, 530 (1-3) :53-58